Stuart Dollow

Head, Global Clinical Development and Medical Affairs

UCB

Stuart Dollow is Head, Global Clinical Development and Medical Affairs at UCB.

After training as a physician with postgraduate work in general medicine and NHS general practice, Stuart joined Roche working initially in European Clinical Research and latterly in Medical Affairs. He subsequently joined GlaxoSmithKline working in both the UK and USA in a wide set of roles, ranging from Clinical Pharmacology to Medical Affairs, including Medicines Development Leadership, and spent more than 4 years as UK Medical Director. 

After leaving GSK, Stuart spent just over two years at Norgine as Chief Development Officer, before joining Takeda initially leading European Development, and later as Development Head for Europe and the Americas. After leaving Takeda, Stuart founded Vermilion Life Sciences, consulting on medicines development. During this time he worked as a work stream Champion and Advisory Board member for the UK Government’s Accelerated Access Review.

Stuart is also a Trustee of the Faculty of Pharmaceutical Medicine, and a Board Member of the Human Tissue Authority.